GAL3ST3

Across TCGA pan-cancer cohorts, GAL3ST3 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GAL3ST3 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher GAL3ST3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GAL3ST3 expression acts as an unfavorable survival marker.

HNSC, LUAD, and MESO are the cancer types where GAL3ST3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	III,IV	0.156	0.726	.002	36	view →
LUAD	OS	Median	II,III,IV	0.109	0.750	<.001	32	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
LIHC	DFS	Median	All	0.043	0.527	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GAL3ST3–HNSC (OS)

Open the HNSC breakdown →